Ireland· IE-PA-PA25299/001/001
Nimotop 30 mg film-coated tablets
A nimodipine product containing nimodipine, registered in Ireland by Laboratoire X.O. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nimodipine is registered in 14 of 19 countries.
Countries holding a registration under ATC C08CA06 (nimodipine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Nimodipine · ATC C08CA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nimodipine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $5.28 in France to $7.99 in Switzerland — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nimodipine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.99
- FR France$5.28
The record
At a glance
HPRA (Ireland)- Active substance
- Nimodipine
- Manufacturer
- Laboratoire X.O
- Country
- Ireland (IE)
- ATC code
- C08CA06
- ATC class
- Nimodipine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA25299/001/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
202 interactions on record for nimodipine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nimodipine · interactions on record
202 records
- 15 severe
- 164 moderate
- 1 minor
- 20 info
Most severe, free to view
- DolasetronA04AA04severe
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nimodipine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandNimotop SDelfarma Sp. z o.o.
- CzechiaNIMOTOP SLaboratoire X.O, Saint-Cloud Cedex
- SpainBRAINAL 30 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAristo Pharma Iberia S.L.
- FinlandNimotopParanova Oy
- SwedenNimotop 30 mg Filmdragerad tablettLaboratoire X.O
- FranceNIMOTOP 30 mg, comprimé pelliculéLABORATOIRE XO
- NetherlandsNimotop 30 mg, filmomhulde tablettenLaboratoire X.O.
- NorwayNimotopLaboratoire X.O.
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Nimotop
- Belgium · Nimotop
- Bulgaria · Нимотоп S
- Cyprus · Nemotan
- Czechia · Dilceren, Nimotop S
- Germany · Nimodipin Carinopharm, Nimodipin Ethypharm
- Denmark · Nimotop
- Estonia · Nimotop
- Spain · Brainal, Nimodipino Altan
- Finland · Nimotop
- France · Nimodipine Altan, Nimotop
- United Kingdom (Northern Ireland) · Nimotop
- Greece · Befimat, Curban
- Croatia · Nimotop S
- Italy · Iskidrop, Nimobrain
- Luxembourg · Nimotop
- Latvia · Nimotop
- Netherlands · Nimotop
- Norway · Nimotop
- Poland · Nimotop S
- Portugal · Brainox, Modina
- Romania · Nimotop
- Sweden · Nimotop
- Slovenia · Nimodipin Bayer, Nimodipin Laboratoire X.O
- Slovakia · Dilceren Pro Infusione, Nemotan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1e88b91a-ef19-4ebc-be96-ce1a0640571f GET /v1/drugs/1e88b91a-ef19-4ebc-be96-ce1a0640571f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"C08CA",
"C08CA06"
],
"strength": null,
"pa_number": "PA25299/001/001",
"substances": [
"Nimodipine"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "15/02/1994",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nimodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.